Statins are one of the key drugs in the treatment of cardiology patients. They lower LDL cholesterol levels, thereby reducing the risk of acute cardiovascular events. Statins are among the best studied drugs, and have been proven to be effective and safe in the treatment of dyslipidemia. Data presented in studies on the prevalence of statin intolerance (SI) varies widely, according to some studies, statin tolerance is the same as placebo, however, this is a common problem in clinical practice. The most common reported symptoms of SI include muscle pain. Patients are often afraid of starting satin treatment because of possible side effects. The appearance of myopathy in patients results in their discontinuation of therapy, which results in increased cardiovascular risk. In order to minimize the risk of SI, particularly statin-associated muscular pain (SI), a key role is played by discussion with the patient, exclusion of nocebo effects, identification of risk factors, dose modification and possible discontinuation of the drug. The purpose of this paper is to review the problem of the most common of the adverse effects of statins- myopathy, in terms of incidence, probable cause, and recommended treatment of patients.

Introduction: Obesity is a well-known risk factor for many health problems. Recently, the increasing number of obese pregnant patients deserves our special attention, because maternal obesity is associated with numerous complications during the antepartum, intrapartum, and immediate postpartum stages of pregnancy. Purpose of the study: The aim of this study is to collect and summarize the latest views on maternal obesity in pregnancy and highlights the complications associated with it. Material and methods: Literature review was performed in English different databases, using keywords: morbid obesity, super-obesity, maternal obesity, pregnancy, complications. Results and conclusions: In our systematic review we would like to present the most important threats of obesity among pregnant women such as: cardiovascular, respiratory, endocrinology and gestational weight gain problems; pregnancy loss; fetal anomalies; anesthetic and delivery problems; breastfeeding disorders; problems with contraception and long-distant effects in a child's adult life. Therapeutic success of such a pregnancy should consist of the cooperation of many specialists. This phenomenon of maternal obesity will certainly spread in the future and for this reason - awareness of this problem is very important for both patients and physicians taking care of them.

Introduction: Hypertension is most important risk factor for cardiovascular disease (CD) and stroke, two of the leading causes of death in adults worldwide. Even though over last decade there has been improvement in increasing the awareness, treatment, and control of hypertension, undiagnosed and uncontrolled hypertension remain one of main public health challenges. In order to make progress in dealing with this problem it important to understand in which areas of the treatment strategy appropriate changes have not yet been implemented. First step to do this is to improve our understanding of the factors that affect the treatment and control of hypertension. International Guidelines for hypertension recommend the same hypertension management for both sexes, however studies reveal that there are actual differences in hypertension management. Purpose of the study: The aim of this study was to conduct a paper review to provide most comprehensive contemporary estimates of sex differences in the awareness, treatment, and control of hypertension. Material and method: A literature review was conducted in English language databases, based only on original articles, regarding awareness, control and treatment of hypertension, using key words: ‘hypertension’, ‘sex- differences’, ‘hypertension treatment’, ‘gender gap’, ‘public health’. Results and conclusions: Based on researched studies we can state that woman have higher awareness, treatment and control rates for hypertension than men worldwide [4,5,6,7,8,9,10]. This suggests that, the guidelines for the treatment and management of hypertension should be gender specific.

Introduction and purpose: Eating disorders are an ever-growing problem, both in the general population and also in the population of pediatric patients with type 1 diabetes mellitus. However, for this specific group of patients, there is a twofold higher risk of developing eating disorders, the occurrence of additional distinct forms of these disorders, the so-called diabulimia - consisting of deliberate restriction of insulin delivery or skipping insulin doses, which can consequently lead to poor metabolic control of diabetes , and even threaten the lives of patients. The purpose of this work is to present the current state of knowledge on the diagnosis, prevention and treatment of eating disorders in children and adolescents with type 1 diabetes. The state of knowladge: The background of the onset of eating disorders in pediatric patients with type 1 diabetes mellitus includes the lowered self-esteem accompanying early adolescence, stress, excessive focus on external appearance, as well as difficulties in accepting the diagnosis and a rather strict dietary regime. Since the treatment of eating disorders is long and difficult, the most important goal becomes effective prevention and rapid selection of patients with a predisposition to develop such disorders. The first screening tools - SEEDS, m-SCOFF and DEPS-R questionnaires - have already been developed, and the effectiveness of therapy sessions aimed at this group of patients is also being studied.  Summary: Therapy of eating disorders in patients with type 1 diabetes should be targeted at this specific patient population. It requires cooperation and communication of teams dealing separately with these diseases, education of the staff and their thorough knowledge of the background of the problem, prompt action and, above all, the development of specific guidelines for management, methods of prevention and the earliest possible start of treatment, which will also include the patient's caregivers.

Introduction and purpose According to the WHO, overweight and obesity are defined as excessive or abnormal accumulation of adipose tissue, leading to deterioration of health. Excessive body weight is a constantly growing public health problem that has reached the scale of a pandemic. Currently, there is ample evidence that excess body weight increases the risk of developing cancer and worsens the prognosis. The aim of this review is to analyze the impact of overweight and obesity on cancer development and prognosis, and to elucidate pathogenesis. State of knowledge  Based on the current state of knowledge in epidemiology, it is estimated that approximately 20% of all malignancies are related to excessive body weight. So far, there is sufficient evidence to support an association between excess body fat and 13 out of 24 cancer sites: esophagus, gastric cardia, colon, liver, gallbladder, pancreas, postmenopausal breast, endometrium, ovary, kidney, meningioma, thyroid and multiple myeloma. Adipose tissue cells produce growth factors, hormones and cytokines that can interfere with the regulation of cell growth and survival. Excess adipose tissue leads to systemic chronic inflammation, oxidative stress, insulin resistance, hyperinsulinemia, increase in sex hormones,  increase in leptin levels and a decrease in adiponectin levels. This leads to DNA defects, stimulation of angiogenesis, cell proliferation and inhibition of apoptosis, and thus promotes the development of cancer. In addition, studies have estimated that excess body weight is responsible for 14% of cancer deaths in men and 20% in women. Conclusions Due to the increasing problem of obesity and cancer worldwide and the proven causal relationship between these diseases, it is necessary to intensify nutrition education and promote a healthy lifestyle in order to minimize excessive body weight, and thus reduce the incidence of cancer.